The importance of sclerostin to skeletal homeostasis is well-established, and romosozumab (anti-sclerostin monoclonal antibody) has emerged as a potent osteoanabolic agent in osteoporosis treatment [32, 33]. The gene discussed is SOST; the disease is osteoporosis.